Noticias de PRLD_US

Noticias del mercado

Últimas noticias sobre PRLD_US — 60 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: PRLD_US ✕ 60 resultados
04/05/2026 PRLD_US — GuruFocus
PRLD Initiates Coverage On Prelude Therapeutics -- Price Target Announced at $9.00
01/05/2026 PRLD_US — TradingView
Prelude Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview
01/05/2026 PRLD_US — Yahoo Finance
Prelude Therapeutics (PRLD) Presents Preclinical Data for KAT6A Degarader PRT13722 in Breast Cancer
29/04/2026 PRLD_US — Stock Titan ES ← EN
Prelude Therapeutics (NASDAQ:PRLD) describe los votos por poder para 2026 sobre directores, remuneración y auditor

Prelude Therapeutics (NASDAQ: PRLD) outlines 2026 proxy votes on directors, pay and auditor

29/04/2026 PRLD_US — Stock Titan
[ARS] Prelude Therapeutics Inc SEC Filing
28/04/2026 PRLD_US — Stock Titan ES ← EN
RA Capital informa una participación de 7,88 millones de acciones en Prelude Therapeutics (PRLD)

RA Capital reports 7.88M-share Prelude Therapeutics (PRLD) stake

27/04/2026 PRLD_US — GuruFocus
PRLD Maintained by HC Wainwright & Co. -- Price Target Raised to $8
24/04/2026 PRLD_US — Investing.com
Thursday’s insider trading: Major buys at Prelude, sells at NuScale
24/04/2026 PRLD_US — Investing.com South Africa
Prelude Therapeutics director David P. Bonita acquires $12.5 million in stock By Investing.com
23/04/2026 PRLD_US — Investing.com India
Prelude Therapeutics director David P. Bonita acquires $12.5 million in stock
23/04/2026 PRLD_US — Investing.com ES ← EN
El director de Prelude Therapeutics, David P. Bonita, adquiere acciones por valor de 12,5 millones de dólares

Prelude Therapeutics director David P. Bonita acquires $12.5 million in stock

23/04/2026 PRLD_US — Investing.com ES ← EN
Las entidades de Orbimed adquieren 12,5 millones de dólares en acciones de Prelude Therapeutics Por Investing.com

Orbimed entities acquire $12.5m in Prelude Therapeutics stock By Investing.com

23/04/2026 PRLD_US — Investing.com ES ← EN
Las entidades de Orbimed adquieren 12,5 millones de dólares en acciones de Prelude Therapeutics

Orbimed entities acquire $12.5m in Prelude Therapeutics stock

23/04/2026 PRLD_US — Stock Titan
OrbiMed funds boost Prelude Therapeutics (NASDAQ: PRLD) stake with 2.82M-share buy
23/04/2026 PRLD_US — Investing.com Nigeria
Prelude Therapeutics director David P. Bonita acquires $12.5 million in stock
23/04/2026 PRLD_US — Investing.com Nigeria
Orbimed entities acquire $12.5m in Prelude Therapeutics stock By Investing.com
23/04/2026 PRLD_US — Investing.com
Orbimed entities acquire $12.5m in Prelude Therapeutics stock
23/04/2026 PRLD_US — Stock Titan
OrbiMed funds add Prelude Therapeutics (PRLD) shares at $4.44 in offering
23/04/2026 PRLD_US — Investing.com
Prelude Therapeutics director David P. Bonita acquires $12.5 million in stock
21/04/2026 PRLD_US — TradingView
Prelude Therapeutics Enters Underwriting for $85.5 Million Equity Offering Led by RA Capital

Página 2 de 3

keyboard_arrow_up